Effector Therapeutics Performance
| EFTRDelisted Stock | USD 0.13 0.03 30.00% |
The firm shows a Beta (market volatility) of 0.61, which means possible diversification benefits within a given portfolio. As returns on the market increase, Effector Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Effector Therapeutics is expected to be smaller as well. Effector Therapeutics right now shows a risk of 0.0%. Please confirm Effector Therapeutics treynor ratio, as well as the relationship between the kurtosis and day typical price , to decide if Effector Therapeutics will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Effector Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Effector Therapeutics is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 8.7 M |
Effector |
Effector Therapeutics Relative Risk vs. Return Landscape
If you would invest 13.00 in Effector Therapeutics on November 1, 2024 and sell it today you would earn a total of 0.00 from holding Effector Therapeutics or generate 0.0% return on investment over 90 days. Effector Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Effector, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Effector Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Effector Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Effector Therapeutics, and traders can use it to determine the average amount a Effector Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| EFTR |
Based on monthly moving average Effector Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Effector Therapeutics by adding Effector Therapeutics to a well-diversified portfolio.
Effector Therapeutics Fundamentals Growth
Effector Stock prices reflect investors' perceptions of the future prospects and financial health of Effector Therapeutics, and Effector Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Effector Stock performance.
| Return On Equity | -9.47 | ||||
| Return On Asset | -0.83 | ||||
| Current Valuation | (4.52 M) | ||||
| Shares Outstanding | 4.7 M | ||||
| Price To Earning | 1.03 X | ||||
| Price To Book | 13.38 X | ||||
| Price To Sales | 69.65 X | ||||
| EBITDA | (33.73 M) | ||||
| Cash And Equivalents | 41.04 M | ||||
| Cash Per Share | 0.99 X | ||||
| Total Debt | 19.45 M | ||||
| Debt To Equity | 1.03 % | ||||
| Book Value Per Share | 0.21 X | ||||
| Cash Flow From Operations | (29.55 M) | ||||
| Earnings Per Share | (12.57) X | ||||
| Total Asset | 20.54 M | ||||
| Retained Earnings | (179.38 M) | ||||
About Effector Therapeutics Performance
Assessing Effector Therapeutics' fundamental ratios provides investors with valuable insights into Effector Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Effector Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California. Effector Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people.Things to note about Effector Therapeutics performance evaluation
Checking the ongoing alerts about Effector Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Effector Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Effector Therapeutics is not yet fully synchronised with the market data | |
| Effector Therapeutics has some characteristics of a very speculative penny stock | |
| Effector Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (35.81 M) with loss before overhead, payroll, taxes, and interest of (19.76 M). | |
| Effector Therapeutics currently holds about 41.04 M in cash with (29.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.99, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Effector Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Effector Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Effector Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Effector Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Effector Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Effector Therapeutics' stock. These opinions can provide insight into Effector Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Consideration for investing in Effector Stock
If you are still planning to invest in Effector Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Effector Therapeutics' history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |